Checkpoint Inhibitor Refractory Cancer Epidemiology Research Report 2021-2030 - ResearchAndMarkets.com

The "Checkpoint Inhibitor Refractory Cancer - Epidemiology Forecast 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

This 'Checkpoint-inhibitor Refractory Cancer - Epidemiology Forecast - 2030' report delivers an in-depth understanding of Checkpoint-inhibitor Refractory Cancer, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Checkpoint-inhibitor Refractory Cancer Epidemiology

The Checkpoint-inhibitor Refractory Cancer epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool, trends, and assumptions.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Checkpoint-inhibitor Refractory Cancer symptoms epidemiology segmented as the Incidence by tumor type, Checkpoint-inhibitor-treated patients and Checkpoint-inhibitor refractory patients. The report includes the incident scenario of Checkpoint-inhibitor Refractory Cancer symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country-wise Checkpoint-inhibitor Refractory Cancer Epidemiology

The epidemiology segment also provides the Checkpoint-inhibitor Refractory Cancer epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The incident cases of Checkpoint-inhibitor Refractory Cancer-associated in 7MM countries were 156,370 in 2020.

• As per the estimates, the United States has the largest incident population of Checkpoint-inhibitor Refractory Cancer.
• Among the EU5 countries, Germany had the highest incident cases of Checkpoint-inhibitor Refractory Cancer, followed by France. On the other hand, Spain had the lowest incident cases with 7,701 cases in 2020.

Key Topics Covered:

1 Key Insights

2 Report Introduction

3 Checkpoint-inhibitor Refractory Cancer Market Overview at a Glance

3.1 Patient Share (%) Distribution of Checkpoint-inhibitor Refractory Cancer in 2018

3.2 Patient Share (%) Distribution of Checkpoint-inhibitor Refractory Cancer in 2030

4 Executive Summary of Checkpoint-inhibitor Refractory Cancer

5 Disease Background and Overview

5.1 Introduction

5.2 Scientific Overview

5.3 Cancer-Immunity Cycle

5.4 Checkpoint blockade of the CTLA-4 pathway

5.5 Checkpoint blockade of the PD-1/PD-L1

5.6 Next-generation immune checkpoints for cancer therapy

5.7 Solid tumors

5.7.1 Urothelial Carcinoma

5.7.1.1 Diagnosis

5.7.1.2 Treatment

5.7.1.3 Guidelines for Bladder Cancer

5.7.1.4 The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up

5.7.2 NSCLC

5.7.3 Melanoma

5.7.4 Renal cell carcinoma

5.7.5 Hodgkin Lymphoma

5.7.6 Breast Cancer

5.7.7 Cervical Cancer

5.7.8 Mesothelioma

6 Epidemiology and Patient Population

6.1 Key Findings

6.2 7MM Total Incident Population of Checkpoint-inhibitor refractory patients

6.3 Epidemiology of Checkpoint Inhibitors refractory cancer

6.4 The United States

6.4.1 Incidence by tumor type in the United States

6.4.2 Checkpoint-inhibitor treated patients in the United States

6.4.3 Checkpoint-inhibitor refractory patients in the United States

6.5 EU5

6.5.1 Germany

6.5.2 France

6.5.3 Italy

6.5.4 Spain

6.5.5 United Kingdom

6.6 Japan

8 Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/tn5oo

View source version on businesswire.com: https://www.businesswire.com/news/home/20210726005326/en/